fda compounding semaglutide news october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Warns Against Compounded Semaglutide

A meta-analysis of trials on injectable fat reduction found real average improvements but also a wide spread between individuals, which is why session counts vary

An 82% reduction in liver fat with retatrutide could potentially address the disease at an earlier, more reversible stage

An extended clinical trial was conducted with Zepbound

In the context of ED, the first thing to understand about PT-141s safety profile is that its incomplete

Research involving Melanotan II commonly investigates its potential role in melanin-production signaling, UV-response and pigmentation-adaptation pathways, melanocortin receptor activity, appetite-related neuroregulatory mechanisms, and central nervous system melanocortin signaling

The peptide itself is prepared by a licensed compounding pharmacy, since the original FDA-approved drug is no longer manufactured or sold